GeNeuro awarded European patent rights for GNK-301
GeNeuro, an NRx company (Nasdaq: NRXP), received European patent rights for GNK-301, a drug candidate intended to treat amyotrophic lateral sclerosis (ALS).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.